menstruation delayed; frequent headaches/frequent headaches in temples/forehead; insomnia/very disturbed sleep for 3 weeks; off label use; interchange of vaccine products; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory agency. regulatory number: gb-mhra-webcovid-202202191955022320-kt7ls. other case identifier(s): gb-mhra-adr 26626055. a 51 year-old female patient received bnt162b2 (comirnaty), administration date 20jan2022 (lot number: fn5254) as dose 2, single for covid-19 immunisation. relevant medical history included: "endometriosis" (unspecified if ongoing), notes: mild endometriosis; "covid-19", start date: 24jun2021 (unspecified if ongoing), notes: unsure when symptoms stopped; positive covid-19 test. the patient's concomitant medications were not reported. vaccination history included: covid-19 vaccine astrazeneca, administration date: 28mar2021, for covid-19 immunization. the following information was reported: off label use (medically significant) with onset 20jan2022, outcome "unknown", described as "off label use"; interchange of vaccine products (medically significant) with onset 20jan2022, outcome "unknown", described as "interchange of vaccine products"; headache (medically significant) with onset 21jan2022, outcome "not recovered", described as "frequent headaches/frequent headaches in temples/forehead"; insomnia (medically significant) with onset 21jan2022, outcome "recovering", described as "insomnia/very disturbed sleep for 3 weeks"; menstruation delayed (medically significant) with onset 01feb2022, outcome "not recovered", described as "menstruation delayed". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: (25jun2021) yes - positive covid-19 test. no follow-up attempts are possible. no further information is expected